GREENFIELD, Ind., Feb. 21, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced that the Company will participate in the following investor conferences.
On Thursday, February 27, Todd Young, executive vice president and CFO, will participate in a fireside chat at the Bank of America 2025 Animal Health Summit at 12:30 p.m. ET.
On Monday, March 3, Jeff Simmons, president and CEO, will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference at 3:10 p.m. ET.
On Tuesday, March 11, Todd Young, executive vice president and CFO, will participate in a fireside chat at the Barclays 27th Annual Global Healthcare Conference at 9:00 a.m. ET.
Live audio webcasts will be available in the "Events and Presentations" section of Elanco's investor website. Replays will also be available for a limited time at the conclusion of each event.
ABOUT ELANCO
Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With nearly 70 years of animal health heritage, we are committed to helping our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our Elanco Healthy Purpose– all to advance the health of animals, people, the planet and our enterprise. Learn more at www.elanco.com.
Investor Contact: Tiffany Kanaga (765) 740-0314 This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact: Colleen Parr Dekker (317) 989-7011 This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$18.43 |
Daily Change: | -0.20 -1.07 |
Daily Volume: | 5,031,684 |
Market Cap: | US$9.160B |
August 27, 2025 August 07, 2025 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load